- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- PF-05175157, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- DeLand, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–83
of 83
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers
- Interventions
- Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/500 mg, CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Healthy Volunteers
- Interventions
- Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg, CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, Canagliflozin, Sitagliptin, Metformin immediate release
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 45
- States / cities
- Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 30
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Canagliflozin, Liraglutide
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- SGLT2, Metformin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin 50 mg, Canagliflozin 100 mg, Metformin Extended Release (XR)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Diabetes mellitus Type 2 De-escalation treatment (DET)
- Drug
- Lead sponsor
- Sciema UG
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin 50 mg, Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 2
- States / cities
- Fort Myers, Florida • Miramar, Florida
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- JNJ 28431754, Placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Chula Vista, California